Manchester, UK – 5 January 2016 – Premaitha Health PLC (AIM: NIPT, “Premaitha” or the “Company”), developer of the IONA® test, the first CE-marked non-invasive prenatal (NIPT) in vitro diagnostic kit, has launched a bespoke information management system to support the Company’s global clinical laboratory customers with a paperless data tracking solution.
The Premaitha Workflow Manager software interfaces with all instruments in the IONA® test’s workflow across every stage of the process, including DNA extraction, library preparation, sequencing chip preparation, sequencing and analysis. It provides a simple way to comprehensively track clinical sample and patient data, removing the need for labour-intensive manual monitoring.
The software has been developed in partnership with Sagentia, a leading global science, product and technology development company who developed the software based on the specific needs of clinical laboratories currently using the IONA® test. The system is available to new and existing in-house customers using the IONA® test automated workflow.
One customer already using the Premaitha Workflow Manager is St George’s University Hospital NHS Foundation Trust, London, the UK’s first Centre of Excellence for non-invasive prenatal screening. St George’s offer pregnant women in their region the ‘SAFE test’ which is powered by the IONA® test.
Mr John Short, Technical and R&D Manager at St George’s NHS Hospital Trust said: “At St George’s University Hospital NHS Foundation Trust we have established the ‘SAFE test’ supported by Premaitha. We are fortuitous to be the first site to deploy the Premaitha Workflow Manager system as we have found it greatly enhances the robustness and traceability of the service whilst reducing operator time.
“The workflow manager has streamlined the laboratory process by offering a near paperless protocol enabling us to provide a rapid five day reporting time. Overall we are very impressed with this well thought out, easy to use and intelligent IT system, which in combination with the IONA® assay, places the SAFE test at the forefront of molecular screening services.”
Paul Wilkins, Senior Vice President of Medical at Sagentia, said: “The IONA® test already has tremendous clinical utility but the process simplification provided by the Premaitha Workflow Manager software should make a significant difference to laboratories, greatly enhancing market adoption.”
The IONA® test estimates the risk of a fetus having Down’s syndrome or other serious genetic diseases. It has a higher detection rate and lower false positive rate than existing screening tests, giving pregnant women, their families and doctors greater confidence in the result and reducing the need for unnecessary invasive follow-up tests and the associated anxiety and stress. The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha’s clinical laboratory customers to perform the test in their own facilities.
- ENDS -
Notes To Editors
About Premaitha Health
Premaitha is an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal screening (NIPT) and other applications. Premaitha’s flagship product, the IONA® test is the first non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer CE-marked NIPT in-house for the first time.
The IONA® test estimates the risk of a fetus having Down’s syndrome or other serious genetic diseases. The IONA® test has a higher detection rate and lower false positive rate than existing screening tests, giving pregnant women, their families and their doctors greater confidence in the result and reducing the need for unnecessary invasive follow-up tests and the associated anxiety and stress. The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha’s clinical laboratory customers to perform the test in their own facilities. This supports Premaitha’s strategy of accelerating the broad dissemination of NIPT tests to ensure that their benefits are available to pregnant women everywhere.
Premaitha is listed on the London Stock Exchange (AIM). Its R&D, manufacturing and commercial operation is located at Manchester Science Park, UK. For further information please visit www.premaitha.com or email firstname.lastname@example.org
Sagentia is a global science, product and technology development company. Our mission is to help companies maximise the value of their investments in R&D. We partner with clients in the consumer, industrial, medical and oil & gas sectors to help them understand the technology and market landscape, decide their future strategy, solve the complex science and technology challenges and deliver commercially successful products.
Sagentia employs over 150 scientists, engineers and market experts and is part of Science Group, with headquarters in Cambridge, UK and offices in London, Guildford, Boston, Houston and Dubai.
For further information visit www.sagentia.com or email email@example.com
Issued for and on behalf of Premaitha Health by Instinctif Partners.
For more information please contact:
Dr Stephen Little, Chief Executive Officer
Joanne Cross, Head of Marketing
Tel: +44 (0) 161 667 6865
Email: firstname.lastname@example.org /
Science Group plc (formerly Sagentia)
Charlotte Kelley, Marketing Communications Manager
Tel: +44 (0) 1223 875 585
Instinctif Partners (media relations - Premaitha)
Melanie Toyne-Sewell / Jen Lewis / Emma Barlow
Tel: +44 (0) 20 7457 2029 / +44 (0)1260 296 505